Analysts expect that Cigna Corporation (NYSE:CI) will announce sales of $9.95 billion for the current quarter, Zacks reports. Seven analysts have provided estimates for Cigna Corporation’s earnings, with estimates ranging from $9.38 billion to $10.32 billion. Cigna Corporation reported sales of $9.89 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 0.6%. The company is scheduled to report its next earnings report on Thursday, February 1st.

According to Zacks, analysts expect that Cigna Corporation will report full-year sales of $9.95 billion for the current fiscal year, with estimates ranging from $37.78 billion to $41.27 billion. For the next year, analysts anticipate that the firm will post sales of $42.75 billion per share, with estimates ranging from $40.37 billion to $44.82 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Cigna Corporation.

Cigna Corporation (NYSE:CI) last posted its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 EPS for the quarter, beating the Zacks’ consensus estimate of $2.36 by $0.47. Cigna Corporation had a net margin of 5.74% and a return on equity of 18.85%. The business had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.17 billion. During the same quarter last year, the business earned $1.94 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis.

A number of research firms recently commented on CI. Deutsche Bank AG raised their price objective on shares of Cigna Corporation from $175.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday, July 13th. Royal Bank Of Canada reiterated a “buy” rating and set a $182.00 price objective on shares of Cigna Corporation in a research note on Monday, July 24th. BidaskClub upgraded shares of Cigna Corporation from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 18th. Piper Jaffray Companies reiterated a “buy” rating and set a $191.00 price objective on shares of Cigna Corporation in a research note on Sunday, September 17th. Finally, Morgan Stanley raised their price objective on shares of Cigna Corporation from $184.00 to $188.00 and gave the company an “overweight” rating in a research note on Monday, August 7th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Cigna Corporation presently has an average rating of “Buy” and a consensus target price of $201.50.

ILLEGAL ACTIVITY NOTICE: “$9.95 Billion in Sales Expected for Cigna Corporation (CI) This Quarter” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/08/9-95-billion-in-sales-expected-for-cigna-corporation-ci-this-quarter.html.

Cigna Corporation (CI) opened at $205.49 on Wednesday. Cigna Corporation has a 12 month low of $122.35 and a 12 month high of $206.45. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of 0.37. The company has a market cap of $50,542.69, a P/E ratio of 19.75, a P/E/G ratio of 1.56 and a beta of 0.49.

In related news, EVP Lisa R. Bacus sold 2,236 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $179.95, for a total value of $402,368.20. Following the completion of the transaction, the executive vice president now owns 18,501 shares of the company’s stock, valued at approximately $3,329,254.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William D. Zollars sold 1,232 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $187.23, for a total transaction of $230,667.36. The disclosure for this sale can be found here. Insiders sold a total of 3,715 shares of company stock valued at $678,797 in the last ninety days. Company insiders own 1.30% of the company’s stock.

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Cigna Corporation by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,130,735 shares of the health services provider’s stock valued at $2,867,514,000 after buying an additional 424,469 shares during the period. FMR LLC boosted its stake in shares of Cigna Corporation by 6.7% during the 2nd quarter. FMR LLC now owns 6,909,638 shares of the health services provider’s stock valued at $1,156,604,000 after buying an additional 432,978 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Cigna Corporation by 40.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,088,728 shares of the health services provider’s stock valued at $684,413,000 after buying an additional 1,184,632 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Cigna Corporation by 4.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,776,414 shares of the health services provider’s stock valued at $705,889,000 after buying an additional 171,712 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Cigna Corporation by 5.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,655,875 shares of the health services provider’s stock valued at $611,957,000 after buying an additional 180,310 shares during the period. 88.16% of the stock is owned by institutional investors.

About Cigna Corporation

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Get a free copy of the Zacks research report on Cigna Corporation (CI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cigna Corporation (NYSE:CI)

Receive News & Stock Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related stocks with our FREE daily email newsletter.